Income statement
USD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 1M | 3M | 6M | 7M | 2M |
| Gross Profit | -1M | -1M | 3M | 3M | 876K |
| Operating Income | -5M | -7M | -7M | -11M | -4M |
| EBITDA | -4M | -6M | -7M | -11M | -4M |
| Net Income | -5M | -7M | -8M | -11M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Veritas Farms, Inc. (VFRM) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -65.5%, EPS growth of +23.5%, a dividend yield of 0.0%. What stands out right now is revenue -65.5%, EPS +23.5%, free cash flow +19.3% with operating margin -514.0% and ROIC -137.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VFRM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VFRM
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VFRM Max Drawdown
-66.67%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VFRM and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.1M
-71.5% YoY
FY Net Income
-$3.8M
+65.6% YoY
Free Cash Flow
-$4.8M
+65.3% YoY
Revenue Growth
-65.5%
EPS Growth
+23.5%
Gross Margin
-130.1%
Net Margin
-483.9%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 1M | 3M | 6M | 7M | 2M |
| Gross Profit | -1M | -1M | 3M | 3M | 876K |
| Operating Income | -5M | -7M | -7M | -11M | -4M |
| EBITDA | -4M | -6M | -7M | -11M | -4M |
| Net Income | -5M | -7M | -8M | -11M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 55K | 482K | 108K | 1M | 164K |
| Total Assets | 7M | 9M | 12M | 14M | 7M |
| Total Liabilities | 7M | 4M | 5M | 2M | 935K |
| Shareholder Equity | -606K | 5M | 8M | 12M | 6M |
| Total Debt | 5M | 2M | 2M | 386K | 510K |
| Net Debt | 5M | 1M | 2M | -691K | 346K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
+66.0% YoY
Capital Expenditures
597K
+58.6% YoY
Free Cash Flow
5M
+65.3% YoY
Key ratios
Gross Margin
-130.1%
Operating Margin
-514.0%
Net Margin
-483.9%
ROE
-243.8%
Debt / Equity
-7.57x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.